1. National Center for Advancing Translational Sciences (NCATS); National Institutes of Health (NIH); Bethesda Maryland USA
2. IRDiRC Scientific Secretariat; Inserm-US14; Rare Diseases Platform; Paris France
3. Orphanet; Inserm-US14; Rare Diseases Platform; Paris France
4. Agence Nationale de la Recherche (ANR); Paris France
5. Shire; Lexington Massachusetts USA (until April 2017)
6. Genetic Alliance; Washington DC USA
7. EURORDIS-Rare Diseases Europe; Paris France
8. Corporate Drug Development; Chiesi Farmaceutici S.p.A.; Italy
9. Children's Hospital of Eastern Ontario Research Institute; University of Ottawa; Ottawa Canada
10. Genetic Services of Western Australia; King Edward Memorial Hospital; Perth Australia
11. Western Australian Register of Developmental Anomalies; Perth Australia
12. National Centre for Rare Diseases; Istituto Superiore di Sanità; Rome Italy
13. Institute of Genetic Medicine; Newcastle University; Newcastle upon Tyne UK
14. Japan Agency for Medical Research and Development (AMED); Tokyo Japan
15. Sanofi Genzyme; Cambridge Massachusetts USA
16. Directorate General for Research and Innovation (DG RTD); European Commission; Brussels Belgium (until April 2017)
17. Merck & Co. Inc.; Upper Gwynedd; Pennsylvania USA (from June 2017)
18. National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH); Bethesda Maryland USA
19. Office of Population Health Genomics; Public Health Division; Department of Health; Government of Western Australia; Perth Australia